[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Ischemic Heart Disease Drugs Market Report 2018

January 2018 | 99 pages | ID: UA567A98582EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Ischemic Heart Disease Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Ischemic Heart Disease Drugs in these regions, from 2012 to 2022 (forecast).
United States Ischemic Heart Disease Drugs market competition by top manufacturers/players, with Ischemic Heart Disease Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • AstraZeneca
  • Bayer
  • Actelion
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Anti-dyslipidemic Drugs
  • Calcium Channel Blockers
  • Antithrombotic Agents
  • ACE Inhibitors
  • Vasodilators
  • Beta-blockers
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Angina Pectoris
  • Myocardial Infarction
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Ischemic Heart Disease Drugs Market Report 2017

1 ISCHEMIC HEART DISEASE DRUGS OVERVIEW

1.1 Product Overview and Scope of Ischemic Heart Disease Drugs
1.2 Classification of Ischemic Heart Disease Drugs by Product Category
  1.2.1 United States Ischemic Heart Disease Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Ischemic Heart Disease Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Anti-dyslipidemic Drugs
  1.2.4 Calcium Channel Blockers
  1.2.5 Antithrombotic Agents
  1.2.6 ACE Inhibitors
  1.2.7 Vasodilators
  1.2.8 Beta-blockers
1.3 United States Ischemic Heart Disease Drugs Market by Application/End Users
  1.3.1 United States Ischemic Heart Disease Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Angina Pectoris
  1.3.3 Myocardial Infarction
1.4 United States Ischemic Heart Disease Drugs Market by Region
  1.4.1 United States Ischemic Heart Disease Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
  1.4.5 New England Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
  1.4.6 The South Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Ischemic Heart Disease Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Ischemic Heart Disease Drugs (2012-2022)
  1.5.1 United States Ischemic Heart Disease Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Ischemic Heart Disease Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES ISCHEMIC HEART DISEASE DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Ischemic Heart Disease Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Ischemic Heart Disease Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Ischemic Heart Disease Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Ischemic Heart Disease Drugs Market Competitive Situation and Trends
  2.4.1 United States Ischemic Heart Disease Drugs Market Concentration Rate
  2.4.2 United States Ischemic Heart Disease Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Ischemic Heart Disease Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES ISCHEMIC HEART DISEASE DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Ischemic Heart Disease Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Ischemic Heart Disease Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Ischemic Heart Disease Drugs Price by Region (2012-2017)

4 UNITED STATES ISCHEMIC HEART DISEASE DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Ischemic Heart Disease Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Ischemic Heart Disease Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Ischemic Heart Disease Drugs Price by Type (2012-2017)
4.4 United States Ischemic Heart Disease Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES ISCHEMIC HEART DISEASE DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Ischemic Heart Disease Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Ischemic Heart Disease Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES ISCHEMIC HEART DISEASE DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 AstraZeneca
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Ischemic Heart Disease Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 AstraZeneca Ischemic Heart Disease Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bayer
  6.2.2 Ischemic Heart Disease Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bayer Ischemic Heart Disease Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Actelion
  6.3.2 Ischemic Heart Disease Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Actelion Ischemic Heart Disease Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Bristol-Myers Squibb
  6.4.2 Ischemic Heart Disease Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Boehringer Ingelheim
  6.5.2 Ischemic Heart Disease Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Boehringer Ingelheim Ischemic Heart Disease Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview

7 ISCHEMIC HEART DISEASE DRUGS MANUFACTURING COST ANALYSIS

7.1 Ischemic Heart Disease Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Ischemic Heart Disease Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Ischemic Heart Disease Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Ischemic Heart Disease Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES ISCHEMIC HEART DISEASE DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Ischemic Heart Disease Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Ischemic Heart Disease Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Ischemic Heart Disease Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Ischemic Heart Disease Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Ischemic Heart Disease Drugs
Figure United States Ischemic Heart Disease Drugs Market Size (MT) by Type (2012-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Anti-dyslipidemic Drugs Product Picture
Figure Calcium Channel Blockers Product Picture
Figure Antithrombotic Agents Product Picture
Figure ACE Inhibitors Product Picture
Figure Vasodilators Product Picture
Figure Beta-blockers Product Picture
Figure United States Ischemic Heart Disease Drugs Market Size (MT) by Application (2012-2022)
Figure United States Sales Market Share of Ischemic Heart Disease Drugs by Application in 2016
Figure Angina Pectoris Examples
Table Key Downstream Customer in Angina Pectoris
Figure Myocardial Infarction Examples
Table Key Downstream Customer in Myocardial Infarction
Figure United States Ischemic Heart Disease Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ischemic Heart Disease Drugs Sales (MT) and Growth Rate (2012-2022)
Figure United States Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ischemic Heart Disease Drugs Market Major Players Product Sales Volume (MT) (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales (MT) of Key Players/Suppliers (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ischemic Heart Disease Drugs Sales Share by Players/Suppliers
Figure 2017 United States Ischemic Heart Disease Drugs Sales Share by Players/Suppliers
Figure United States Ischemic Heart Disease Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Ischemic Heart Disease Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Ischemic Heart Disease Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ischemic Heart Disease Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Ischemic Heart Disease Drugs Revenue Share by Players/Suppliers
Table United States Market Ischemic Heart Disease Drugs Average Price (USD/Kg) of Key Players/Suppliers (2012-2017)
Figure United States Market Ischemic Heart Disease Drugs Average Price (USD/Kg) of Key Players/Suppliers in 2016
Figure United States Ischemic Heart Disease Drugs Market Share of Top 3 Players/Suppliers
Figure United States Ischemic Heart Disease Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Ischemic Heart Disease Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Ischemic Heart Disease Drugs Product Category
Table United States Ischemic Heart Disease Drugs Sales (MT) by Region (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales Share by Region (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Share by Region (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Market Share by Region in 2016
Table United States Ischemic Heart Disease Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Ischemic Heart Disease Drugs Revenue Share by Region (2012-2017)
Figure United States Ischemic Heart Disease Drugs Revenue Market Share by Region (2012-2017)
Figure United States Ischemic Heart Disease Drugs Revenue Market Share by Region in 2016
Table United States Ischemic Heart Disease Drugs Price (USD/Kg) by Region (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales (MT) by Type (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales Share by Type (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Share by Type (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Market Share by Type in 2016
Table United States Ischemic Heart Disease Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Ischemic Heart Disease Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Ischemic Heart Disease Drugs by Type (2012-2017)
Figure Revenue Market Share of Ischemic Heart Disease Drugs by Type in 2016
Table United States Ischemic Heart Disease Drugs Price (USD/Kg) by Types (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Growth Rate by Type (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales (MT) by Application (2012-2017)
Table United States Ischemic Heart Disease Drugs Sales Market Share by Application (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Market Share by Application (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Market Share by Application in 2016
Table United States Ischemic Heart Disease Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Ischemic Heart Disease Drugs Sales Growth Rate by Application (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Ischemic Heart Disease Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure AstraZeneca Ischemic Heart Disease Drugs Sales Growth Rate (2012-2017)
Figure AstraZeneca Ischemic Heart Disease Drugs Sales Market Share in United States (2012-2017)
Figure AstraZeneca Ischemic Heart Disease Drugs Revenue Market Share in United States (2012-2017)
Table Bayer Basic Information List
Table Bayer Ischemic Heart Disease Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bayer Ischemic Heart Disease Drugs Sales Growth Rate (2012-2017)
Figure Bayer Ischemic Heart Disease Drugs Sales Market Share in United States (2012-2017)
Figure Bayer Ischemic Heart Disease Drugs Revenue Market Share in United States (2012-2017)
Table Actelion Basic Information List
Table Actelion Ischemic Heart Disease Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Actelion Ischemic Heart Disease Drugs Sales Growth Rate (2012-2017)
Figure Actelion Ischemic Heart Disease Drugs Sales Market Share in United States (2012-2017)
Figure Actelion Ischemic Heart Disease Drugs Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Ischemic Heart Disease Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Ischemic Heart Disease Drugs Revenue Market Share in United States (2012-2017)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Ischemic Heart Disease Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim Ischemic Heart Disease Drugs Sales Growth Rate (2012-2017)
Figure Boehringer Ingelheim Ischemic Heart Disease Drugs Sales Market Share in United States (2012-2017)
Figure Boehringer Ingelheim Ischemic Heart Disease Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Ischemic Heart Disease Drugs
Figure Manufacturing Process Analysis of Ischemic Heart Disease Drugs
Figure Ischemic Heart Disease Drugs Industrial Chain Analysis
Table Raw Materials Sources of Ischemic Heart Disease Drugs Major Players/Suppliers in 2016
Table Major Buyers of Ischemic Heart Disease Drugs
Table Distributors/Traders List
Figure United States Ischemic Heart Disease Drugs Sales Volume (MT) and Growth Rate Forecast (2017-2022)
Figure United States Ischemic Heart Disease Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Ischemic Heart Disease Drugs Price (USD/Kg) Trend Forecast (2017-2022)
Table United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Type in 2022
Table United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Application in 2022
Table United States Ischemic Heart Disease Drugs Sales Volume (MT) Forecast by Region (2017-2022)
Table United States Ischemic Heart Disease Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ischemic Heart Disease Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories